Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential.
Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential.
复制标题
乳腺癌的工程过继 T 细胞疗法：当前进展、挑战和潜力。
DOI：
10.3390/cancers16010124
复制
发表时间：
2023-12-26
期刊：
影响因子：
5.2
通讯作者：
Hoyos, Valentina
中科院分区：
文献类型：
--
作者：
Chamorro, Diego F.;Somes, Lauren K.;Hoyos, Valentina
乳腺癌是女性癌症的主要形式，这凸显了对创新靶向疗法的迫切需求。工程过继细胞疗法代表了一种突破性的方法，使患者的免疫细胞能够通过癌症特异性受体精确靶向肿瘤。令人鼓舞的是，临床前研究已经阐明了这种策略的巨大前景。尽管如此，将这项技术转化为临床实践取决于积累更多可靠的临床数据。在这篇综述中，我们对乳腺癌工程细胞疗法的现状进行了全面的研究，深入探讨了它们的局限性和令人信服的增强前景。乳腺癌仍然是一个重大的健康挑战，迫切需要新的治疗方法。本文综述了工程过继性T细胞疗法（E-ACTs）的深入分析，这是癌症免疫治疗的一个创新前沿，重点是它们在乳腺癌中的应用。我们探讨了嵌合抗原受体（CAR）和T细胞受体（TCR）T细胞疗法的发展前景，强调了它们在靶向乳腺癌方面的潜力和挑战。该综述解决了关键障碍，如靶抗原选择，复杂的乳腺癌肿瘤微环境和工程化T细胞的持久性。我们讨论了克服这些障碍的进展，包括增强T细胞功效的策略。最后，我们对该领域当前临床试验的全面分析为E-ACT治疗乳腺癌的未来可能性和方向提供了见解。
Breast cancer stands as the predominant form of cancer identified in women, underscoring the urgent demand for innovative targeted therapies. Engineered adoptive cell therapies represent a groundbreaking approach, empowering the immune cells of patients to precisely target their tumors through cancer-specific receptors. Encouragingly, preclinical studies have illuminated the immense promise of this strategy. Nonetheless, the translation of this technique into clinical practice hinges on the accumulation of additional robust clinical data. Within this review, we offer a comprehensive examination of the current landscape surrounding engineered cell therapies for breast cancer, delving into both their limitations and the compelling prospects for enhancement. Breast cancer remains a significant health challenge, and novel treatment approaches are critically needed. This review presents an in-depth analysis of engineered adoptive T-cell therapies (E-ACTs), an innovative frontier in cancer immunotherapy, focusing on their application in breast cancer. We explore the evolving landscape of chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies, highlighting their potential and challenges in targeting breast cancer. The review addresses key obstacles such as target antigen selection, the complex breast cancer tumor microenvironment, and the persistence of engineered T-cells. We discuss the advances in overcoming these barriers, including strategies to enhance T-cell efficacy. Finally, our comprehensive analysis of the current clinical trials in this area provides insights into the future possibilities and directions of E-ACTs in breast cancer treatment.
登录
查看更多内容
影响因子：
7.2
作者：
Bughda R;Dimou P;D'Souza RR;Klampatsa A
通讯作者：
Klampatsa A
DOI：
10.1039/c5ib00040h
发表时间：
2015-10
期刊：
Integrative biology : quantitative biosciences from nano to macro
影响因子：
--
作者：
Acerbi I;Cassereau L;Dean I;Shi Q;Au A;Park C;Chen YY;Liphardt J;Hwang ES;Weaver VM
通讯作者：
Weaver VM
影响因子：
64.5
作者：
Buck MD;Sowell RT;Kaech SM;Pearce EL
通讯作者：
Pearce EL
影响因子：
4.7
作者：
Nadanaka, Satomi;Tamura, Jun-ichi;Kitagawa, Hiroshi
通讯作者：
Kitagawa, Hiroshi
影响因子：
16.6
作者：
Bronte V;Brandau S;Chen SH;Colombo MP;Frey AB;Greten TF;Mandruzzato S;Murray PJ;Ochoa A;Ostrand-Rosenberg S;Rodriguez PC;Sica A;Umansky V;Vonderheide RH;Gabrilovich DI
通讯作者：
Gabrilovich DI